

RxHighlights

May 2024

[Learn more](#)

New drugs

Drug name manufacturer(s)	Therapeutic category	Indication(s)	Launch information
Imdelltra™ (tarlatamab-dlle)*† Amgen	Bispecific T cell engager antibody	Treatment of adult patients with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy	May 21, 2024
mRESVIA™ (respiratory syncytial virus vaccine) Moderna	Vaccines	Active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older	2024/2025 RSV Season
Myhibbin (mycophenolate mofetil) Liqmeds Worldwide	Immunosuppressive Agents	Prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants	June 3, 2024
Onyda™ XR (clonidine) extended release oral suspension Tris Pharma	Centrally acting alpha2-adrenergic agonist	Treatment of attention deficit hyperactivity disorder as monotherapy and as adjunctive therapy to central nervous system stimulant medications in pediatric patients 6 years of age and older	TBD

*New molecular entity; †Orphan drug; TBD: To be determined

New biosimilars

[Learn more](#)

Drug name manufacturer(s)	Therapeutic category	Indication(s)	Launch information
Bkemv™ (eculizumab-aeeb) [§] Amgen	Recombinant humanized monoclonal antibody (MAb) complement protein C5 inhibitor	Treatment of patients with paroxysmal nocturnal hemoglobinuria to reduce hemolysis; treatment of patients with atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy	March 1, 2025
Cyltezo® (adalimumab-adbm) Boehringer Ingelheim	Tumor necrosis factor	Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis	May 1, 2024
Opuviz™ (afibercept-yszy) [§] Samsung Bioepis/Biogen	Vascular endothelial growth factor inhibitor	Neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy	TBD
Yesafili™ (afibercept-jbvf) [§] , Biocon	Vascular endothelial growth factor inhibitor	Neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy	TBD
Simlandi® (adalimumab-ryvk) [§] Alvotech, Teva	Tumor necrosis factor	Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis	May 20, 2024

TBD: To be determined; §Interchangeable

[Learn more](#)

New generics

Drug name manufacturer(s)	Generic manufacturer(s)	Strength(s) & dosage form(s)	Therapeutic use	Launch information
Halaven® (eribulin) Eisai	Apotex †	1 mg/2 mL solution for injection	Treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen	May 7, 2024

†AP-rated generic version manufacturer; TBD: To be determined

[Learn more](#)

Indications/Label updates

Drug name manufacturer(s)	Type	Description
Breyanzi® (lisocabtagene maraleucel) Bristol Myers Squibb	New indications	Treatment of adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy
		Treatment of adult patients with relapsed or refractory mantle cell lymphoma who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor
Retevmo® (selpercatinib) Eli Lilly	Expanded indications	Treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation who require systemic therapy; advanced or metastatic thyroid cancer with a RET gene fusion, who require systemic therapy and who are radioactive iodine-refractory; locally advanced or metastatic solid tumors with a RET gene fusion, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options

[Learn more](#)

Drug recalls/Withdrawals/Shortages/Discontinuations

Drug name manufacturer(s)	Strength(s) and dosage form(s)	Type	Description
Buprenorphine injection Hospira	0.3 mg base/mL injection	Recall	<p>Hospira announced a voluntary user-level recall of two lots of buprenorphine injection due to the potential for incomplete crimp seals; one customer complaint has been received for one leaking unit.</p> <p>Buprenorphine injection is indicated for the management of pain requiring an opioid analgesic and for which alternate treatments are inadequate.</p>
Labetalol injection Hospira	20 mg/4 mL injection	Recall	<p>Hospira announced a voluntary user-level recall of three lots of labetalol injection due to the potential for incomplete crimp seals; one customer complaint has been received for one leaking unit.</p> <p>Labetalol injection is indicated for control of blood pressure in severe hypertension.</p>
Docetaxel Sagent	160 mg/16 mL (10 mg/mL) injection, 80 mg/8 mL (10 mg/mL) injection	Recall	<p>Sagent announced a user-level recall of two lots of docetaxel injection because of a customer complaint due to potential presence of particulate matter from the stopper in the drug product.</p> <p>Docetaxel is indicated for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.</p>

Key guideline/Literature updates

Topic	Reference
American Society of Colon and Rectal Surgeons – Management of Hemorrhoids	<i>Diseases of the Colon & Rectum</i> . May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia - Version 3.2024	<i>NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia</i> . May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Bladder Cancer - Version 4.2024	<i>NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer</i> . May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Central Nervous System Cancers - Version 1.2024	<i>NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers</i> . May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Cervical Cancer - Version 3.2024	<i>NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer</i> . May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Colon Cancer - Version 3.2024	<i>NCCN Clinical Practice Guidelines in Oncology: Colon Cancer</i> . May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Gastric Cancer - Version 2.2024	<i>NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer</i> . May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Kidney Cancer - Version 4.2024	<i>NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer</i> . May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Melanoma: Uveal - Version 1.2024	<i>NCCN Clinical Practice Guidelines in Oncology: Melanoma: Uveal</i> . May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes - Version 2.2024	<i>NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes</i> . May 2024

Topic	Reference
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer - Version 2.2024	<u>NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal.</u> May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Pediatric Hodgkin Lymphoma - Version 1.2024	<u>NCCN Clinical Practice Guidelines in Oncology: Pediatric Hodgkin Lymphoma.</u> May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas - Version 2.2024	<u>NCCN Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas.</u> May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer - Version 4.2024	<u>NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer.</u> May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: T-Cell Lymphomas - Version 4.2024	<u>NCCN Clinical Practice Guidelines in Oncology: T-Cell Lymphomas.</u> May 2024
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Adolescent and Young Adult (AYA) Oncology - Version 1.2025	<u>NCCN Clinical Practice Guidelines in Oncology: Adolescent and Young Adult (AYA) Oncology.</u> May 2024



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxHighlights® is published by the Optum Rx Clinical Services Department. © 2022 Optum, Inc. All rights reserved. ORX6547968C-TEMPLATE_220208